Gossamer Bio, Inc. (GOSS) Stock Ticker
GOSS right now
Market factors today
Unlock the full GOSS picture
About Gossamer Bio, Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
GOSS stock facts
| Ticker symbol | GOSS |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $70.4M |
| CEO | Faheem Hasnain |
| Employees | 162 |
| Headquarters | San Diego, CA, US |
| IPO date | 2019-02-08 |
| Website | www.gossamerbio.com |
What you can see for GOSS on Tickr
Live GOSS price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the GOSS report.
Rankings
FAQ
What is the ticker symbol for Gossamer Bio, Inc.?
The ticker symbol for Gossamer Bio, Inc. is GOSS, listed on the NASDAQ.
What is GOSS?
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in…